OBJECTIVES To evaluate the cost-effectiveness of glatiramer acetate (Copaxone®) as a disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) compared to intravenous [natalizumab (Tysabri®), alemtuzumab (Lemtrada®)] or subcutaneous injectables [interferon-beta-1b (Betaferon®), interferon-beta-1a 44mcg, 22mcg, 30mcg (Rebif-44®, Rebif-22®, Avonex®)] and oral DMTs [fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), teriflunomide (Aubagio®)]. METHODS A Markov model followed patients over 50 years through 21 health states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and secondary progressive multiple sclerosis (SPMS), respectively, and death (EDSS10). Total treatment costs, quality-adjusted life-years (QALYs) gained and incremental cost-effectiveness ratios (ICERs) were calculated from the Dutch societal perspective. Baseline demographics; transition probabilities; treatment-specific relative risks; and utility values were obtained from published literature. Health resource use was based on the products’ SmPCs. Unit costs were based on national tariffs and published data. A base case analysis considered the direct and indirect costs of treatment. To test the robustness of the results, univariate and probabilistic sensitivity analyses (PSA) were performed. RESULTS Total treatment costs of glatiramer acetate were lower versus teriflunomide, interferon-beta-1a 44mcg, 30mcg, fingolimod, natalizumab, dimethyl fumarate and alemtuzumab; and higher versus interferon-beta-1a 22mcg, interferon-beta-1b, and BSC. Glatiramer acetate dominated interferon-beta-1a 44mcg and 30mcg, and was cost-effective versus other comparators at a willingness-to-pay threshold of €20,000/QALY. The PSA indicated these results were robust. Univariate analysis showed that relative risks of disease progression and drug costs were the most influential model parameters. CONCLUSIONS In the Netherlands, glatiramer acetate is a cost-effective treatment versus a number of other treatments indicated in multiple sclerosis, and results proved robust.